Milind Javle(@JavleMilind) 's Twitter Profileg
Milind Javle

@JavleMilind

Hubert L and Olive Stringer Professor GI Medical Oncology and Attending Physician, MD Anderson Cancer Center
Chair, NCI Task Force Hepatobiliary Cancers

ID:1357532036475596800

calendar_today05-02-2021 03:30:48

683 Tweets

1,3K Followers

325 Following

Follow People
Milind Javle(@JavleMilind) 's Twitter Profile Photo

One of the greatest medical breakthroughs in 2023: Malaria vaccine will soon be available! Generated by Oxford University and Serum Institute of India ⁦Gavi, the Vaccine Alliance⁩ and@Gates foundation. A disease that still claims>600K lives annually. who.int/news/item/21-1…

account_circle
Milind Javle(@JavleMilind) 's Twitter Profile Photo

Relieved to pass ABIM recertification. However, after working in a focused GI cancer field >17 years..was it of any value to get examined in leukemia, NSCLC, breast cancer, GYN, and so on (also $$cost) Is this the best recertification model for subspecialists American Board of Internal Medicine (ABIM)?

account_circle
Madhu Eluri, MD(@MadhuEluri) 's Twitter Profile Photo

Congrats to everyone who passed their boards. Sharing my cheat sheet* i made right before the exam. Thanks to TwoOncDocs and Hemeoncquestions

*these are my personal notes; can’t attest to accuracy use at your own risk

icloud.com/notes/097Kt1lq…

account_circle
Mark Yarchoan(@MarkYarchoan) 's Twitter Profile Photo

IPI+NIVO after prior PD1/L1 in HCC?
➡️Retrospective series, half tx w/ prior BEV/ATEZO (no prior anti-CTLA4)
➡️ORR 22% (7/32)
➡️All responders to late line IPI+NIVO had NONRESPONSE to prior PD1/L1
ncbi.nlm.nih.gov/pmc/articles/P…

IPI+NIVO after prior PD1/L1 in HCC? ➡️Retrospective series, half tx w/ prior BEV/ATEZO (no prior anti-CTLA4) ➡️ORR 22% (7/32) ➡️All responders to late line IPI+NIVO had NONRESPONSE to prior PD1/L1 ncbi.nlm.nih.gov/pmc/articles/P…
account_circle
Milind Javle(@JavleMilind) 's Twitter Profile Photo

Tinengotinib VS. Physician's Choice for Patients With FGFR-altered Cholangiocarcinoma (FIRST-308) classic.clinicaltrials.gov/ct2/show/NCT05… First phase 3 trial: FGFR-inhibitor refractory CCA open! Cholangiocarcinoma Foundation Craine’s Cholangiocarcinoma Crew Melinda Bachini MD Anderson Cancer Center AMMF ENS-CCA

account_circle
Milind Javle(@JavleMilind) 's Twitter Profile Photo

Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma - Journal of Hepatology. Wonderful work by Tim DiPieri and Funda Meric ⁦Cholangiocarcinoma Foundation⁩ ⁦MD Anderson Cancer Center⁩ ⁦ENS-CCA⁩ journal-of-hepatology.eu/article/S0168-…

account_circle
Arndt Vogel(@ArndtVogel) 's Twitter Profile Photo

Convergent MAPK pathway alterations mediate acquired resistance to FGFRi in FGFR2 fusion-positive CCC
Journal of Hepatology
doi.org/10.1016/j.jhep…
👍Additional clinical evidence
👇see also our preclinical work in HEPATOLOGY Journal
doi.org/10.1016/j.jhep…
EASLnews ILCA ESMO - Eur. Oncology

Convergent MAPK pathway alterations mediate acquired resistance to FGFRi in FGFR2 fusion-positive CCC @JHepatology doi.org/10.1016/j.jhep… 👍Additional clinical evidence 👇see also our preclinical work in @HEP_Journal doi.org/10.1016/j.jhep… @EASLnews @ILCAnews @myESMO…
account_circle
Arndt Vogel(@ArndtVogel) 's Twitter Profile Photo

FDA approves pembrolizumab with chemotherapy for biliary tract cancer fda.gov/drugs/resource…
👉good news, more options for our patients...
🧐Let's see how long it will take to get it approved by EMA...
ESMO - Eur. Oncology EASLnews ILCA

FDA approves pembrolizumab with chemotherapy for biliary tract cancer fda.gov/drugs/resource… 👉good news, more options for our patients... 🧐Let's see how long it will take to get it approved by EMA... @myESMO @EASLnews @ILCAnews #livertwitter
account_circle
Amol Patel(@Amolpatel_dr) 's Twitter Profile Photo

Dear Friends, Biliary Tract Cancers are common in India. National and international experts have gathered for a common goal. Huge opportunity for residents to meet the faculties. Don't miss this!
Patients of biliary tract cancers are invited.
riverroute.in/apccf2023

Dear Friends, Biliary Tract Cancers are common in India. National and international experts have gathered for a common goal. Huge opportunity for residents to meet the faculties. Don't miss this! Patients of biliary tract cancers are invited. riverroute.in/apccf2023
account_circle
MD Anderson Cancer Center(@MDAndersonNews) 's Twitter Profile Photo

Results from a Phase II trial led by our Dr. Milind Javle (abstract 95MO) show FGFR inhibitor tinengotinib may allow patients with bile duct cancer to live longer without disease progression.

Learn more: brnw.ch/21wDKC6 Milind Javle ESMO - Eur. Oncology

account_circle
Lisa Craine(@lisamariecraine) 's Twitter Profile Photo

Join us for the Cleveland Clinic Cholangiocarcinoma Symposium on November 10, at Taussig Cancer Center. Learn from Cleveland Clinic experts along with special guest Dr. Milind Javle from MDAnderson.
Craine’s Cholangiocarcinoma Crew Milind Javle Cleveland Clinic

Register at cholangiocarcinoma.org/cleveland-2023/

Join us for the Cleveland Clinic Cholangiocarcinoma Symposium on November 10, at Taussig Cancer Center. Learn from Cleveland Clinic experts along with special guest Dr. Milind Javle from MDAnderson. @CrainesCrew @JavleMilind @ClevelandClinic Register at cholangiocarcinoma.org/cleveland-2023/
account_circle
Milind Javle(@JavleMilind) 's Twitter Profile Photo

Welcome to 6 Asia Pacific Cholangiocarcinoma Conference Mumbai Nov 1/2, 2023. Providers, scientists, patients, caregivers, advocates welcome Tata Memorial Hosp, Registration free: riverroute.in/apccf2023
Cholangiocarcinoma Foundation ENS-CCA AMMF MD Anderson Cancer Center Tata Memorial Centre IndianCancerSociety

Welcome to 6 Asia Pacific Cholangiocarcinoma Conference Mumbai Nov 1/2, 2023. Providers, scientists, patients, caregivers, advocates welcome Tata Memorial Hosp, Registration free: riverroute.in/apccf2023 @curecc @CcaEns @CharityAMMF @MDAndersonNews @TataMemorial @ics_1951
account_circle
Cholangiocarcinoma Foundation(@curecc) 's Twitter Profile Photo

📣Join us for the 2023 Cleveland Regional Symposium on Nov 10 , 2023 at Taussig Cancer Center. Learn about cholangiocarcinoma from Cleveland Clinic experts.

Special guest: Dr. Milind Javle from MD Anderson Cancer Center. Register for this educational event at cholangiocarcinoma.org/cleveland-2023/.

📣Join us for the 2023 Cleveland Regional Symposium on Nov 10 , 2023 at Taussig Cancer Center. Learn about cholangiocarcinoma from Cleveland Clinic experts. Special guest: Dr. @JavleMilind from @MDAndersonNews. Register for this educational event at cholangiocarcinoma.org/cleveland-2023/.
account_circle